MD4643C1 - Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin - Google Patents
Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţinInfo
- Publication number
- MD4643C1 MD4643C1 MDA20160016A MD20160016A MD4643C1 MD 4643 C1 MD4643 C1 MD 4643C1 MD A20160016 A MDA20160016 A MD A20160016A MD 20160016 A MD20160016 A MD 20160016A MD 4643 C1 MD4643 C1 MD 4643C1
- Authority
- MD
- Moldova
- Prior art keywords
- production
- pharmaceutical compositions
- compositions containing
- containing same
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000003406 indolizinyl group Chemical class C=1(C=CN2C=CC=CC12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 208000000587 small cell lung carcinoma Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Invenţia se referă la compuşi cu formula (I):Compuşii, conform invenţiei, pot fi utili în tratamentul formelor de cancer rezistente la chimio- sau radioterapie, în hemopatiile maligne şi cancerul pulmonar cu celule mici.Invenţia se referă, de asemenea, la un procedeu de obţinere a compuşilor cu formula (I) şi la compoziţii farmaceutice care cuprind, cel puţin, un compus cu formula (I) în combinaţie cu unul sau mai mulţi excipienţi acceptabili farmaceutic.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1357265A FR3008976A1 (fr) | 2013-07-23 | 2013-07-23 | "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
| PCT/FR2014/051885 WO2015011397A1 (fr) | 2013-07-23 | 2014-07-22 | Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MD20160016A2 MD20160016A2 (ro) | 2016-07-31 |
| MD4643B1 MD4643B1 (ro) | 2019-08-31 |
| MD4643C1 true MD4643C1 (ro) | 2020-03-31 |
Family
ID=50023640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20160016A MD4643C1 (ro) | 2013-07-23 | 2014-07-22 | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin |
Country Status (49)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2986002B1 (fr) | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3008976A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
| TWI759316B (zh) | 2016-07-22 | 2022-04-01 | 法商施維雅藥廠 | Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物 |
| WO2018158225A1 (en) | 2017-02-28 | 2018-09-07 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof |
| RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| PT3697785T (pt) | 2017-10-18 | 2023-04-03 | Jubilant Epipad LLC | Compostos de imidazopiridina como inibidores de pad |
| FR3072679B1 (fr) | 2017-10-25 | 2020-10-30 | Servier Lab | Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| KR20200085836A (ko) | 2017-11-06 | 2020-07-15 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체 |
| PT3704120T (pt) | 2017-11-24 | 2024-07-03 | Jubilant Episcribe Llc | Compostos heterocíclicos como inibidores de prmt5 |
| BR112020018610A2 (pt) | 2018-03-13 | 2020-12-29 | Jubilant Prodel LLC | Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas |
| CA3138307A1 (en) * | 2019-05-13 | 2020-11-19 | Ecolab Usa Inc. | 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor |
| JP2024508948A (ja) * | 2021-03-12 | 2024-02-28 | エイル セラピューティクス，インコーポレイテッド | Ｂｃｌ－２阻害剤としてのテトラヒドロインドリジン－１－カルボキサミドを有する化合物 |
| TW202408588A (zh) | 2022-05-20 | 2024-03-01 | 瑞士商諾華公司 | 抗體-藥物結合物抗腫瘤化合物及其使用方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100391958C (zh) * | 2001-09-19 | 2008-06-04 | 安万特医药股份有限公司 | 化合物 |
| AU2003234464B2 (en) | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| US20050070570A1 (en) | 2003-06-18 | 2005-03-31 | 4Sc Ag | Novel potassium channels modulators |
| ZA200702257B (en) * | 2004-08-20 | 2009-06-24 | Univ Michigan | Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof |
| WO2006023778A2 (en) * | 2004-08-20 | 2006-03-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| CN101356159A (zh) | 2005-12-22 | 2009-01-28 | 惠氏公司 | 经取代异喹啉-1,3(2h,4h)-二酮类、1-硫代-1,4-二氢-2h-异喹啉-3-酮类和1,4-二氢-3(2h)-异喹啉酮类以及其作为激酶抑制剂的用途 |
| US7902218B2 (en) | 2006-12-12 | 2011-03-08 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinolines as β-secretase inhibitors |
| AU2008242983B2 (en) | 2007-04-16 | 2013-07-11 | Abbvie Inc. | 7-substituted indole Mcl-1 inhibitors |
| PT2149560E (pt) | 2007-05-22 | 2015-07-13 | Astellas Pharma Inc | Composto de tetra-hidroisoquinolina substituído na posição 1 |
| CN102007101A (zh) | 2007-11-30 | 2011-04-06 | 生物区科学管理控股有限公司 | 作为抗菌剂的四氢-异喹啉ppat抑制剂 |
| AU2009215191A1 (en) | 2008-02-13 | 2009-08-20 | Gilead Connecticut, Inc. | 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof |
| PL2252317T3 (pl) | 2008-02-15 | 2014-09-30 | Univ Tufts | Leczenie zwyrodnienia plamki żółtej |
| WO2012162365A1 (en) * | 2011-05-25 | 2012-11-29 | Bristol-Myers Squibb Company | Substituted sulfonamides useful as antiapoptotic bcl inhibitors |
| US20140357633A1 (en) | 2011-12-23 | 2014-12-04 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| KR20140107573A (ko) | 2011-12-23 | 2014-09-04 | 노파르티스 아게 | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 |
| BR112014015308A8 (pt) | 2011-12-23 | 2017-06-13 | Novartis Ag | compostos para inibição da interação de bcl2 com contrapartes de ligação |
| MX2014007725A (es) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
| BR112014015322A8 (pt) | 2011-12-23 | 2017-06-13 | Novartis Ag | compostos e composições para inibir a interação de bcl2 com parceiros de ligação |
| DK2609926T3 (da) | 2011-12-30 | 2014-01-06 | Jakob Hraschan | Forebyggelse eller behandling af smertefulde polyneuropatier ved administration af et aluminiumsilikat |
| FR2986002B1 (fr) * | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3008979B1 (fr) | 2013-07-23 | 2015-07-24 | Servier Lab | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3008976A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" |
-
2013
- 2013-07-23 FR FR1357265A patent/FR3008976A1/fr active Pending
-
2014
- 2014-06-16 JO JOP/2014/0193A patent/JO3310B1/ar active
- 2014-06-24 UY UY35626A patent/UY35626A/es unknown
- 2014-07-03 TW TW103123060A patent/TWI511969B/zh not_active IP Right Cessation
- 2014-07-21 AR ARP140102678A patent/AR099913A1/es unknown
- 2014-07-22 CU CU2016000011A patent/CU24380B1/es unknown
- 2014-07-22 PT PT147586051T patent/PT3024833T/pt unknown
- 2014-07-22 TN TN2016000014A patent/TN2016000014A1/fr unknown
- 2014-07-22 DK DK14758605.1T patent/DK3024833T3/en active
- 2014-07-22 MX MX2016000906A patent/MX365916B/es active IP Right Grant
- 2014-07-22 RS RS20171036A patent/RS56451B1/sr unknown
- 2014-07-22 EP EP14758605.1A patent/EP3024833B1/fr active Active
- 2014-07-22 CA CA2918217A patent/CA2918217C/fr active Active
- 2014-07-22 UA UAA201601430A patent/UA119243C2/uk unknown
- 2014-07-22 AU AU2014294867A patent/AU2014294867B2/en active Active
- 2014-07-22 RU RU2016105999A patent/RU2693629C2/ru active
- 2014-07-22 MD MDA20160016A patent/MD4643C1/ro not_active IP Right Cessation
- 2014-07-22 ES ES14758605.1T patent/ES2650814T3/es active Active
- 2014-07-22 MY MYPI2016700108A patent/MY178251A/en unknown
- 2014-07-22 JP JP2016528588A patent/JP6458029B2/ja active Active
- 2014-07-22 BR BR112016001328-0A patent/BR112016001328B1/pt active IP Right Grant
- 2014-07-22 US US14/906,330 patent/US9944620B2/en active Active
- 2014-07-22 LT LTEP14758605.1T patent/LT3024833T/lt unknown
- 2014-07-22 SG SG10201800580XA patent/SG10201800580XA/en unknown
- 2014-07-22 HU HUE14758605A patent/HUE037498T4/hu unknown
- 2014-07-22 NZ NZ716156A patent/NZ716156A/en unknown
- 2014-07-22 PE PE2016000036A patent/PE20160240A1/es active IP Right Grant
- 2014-07-22 WO PCT/FR2014/051885 patent/WO2015011397A1/fr active Application Filing
- 2014-07-22 SI SI201430461T patent/SI3024833T1/sl unknown
- 2014-07-22 ME MEP-2017-272A patent/ME02922B/me unknown
- 2014-07-22 KR KR1020167004588A patent/KR102007516B1/ko active IP Right Grant
- 2014-07-22 SG SG11201600318RA patent/SG11201600318RA/en unknown
- 2014-07-22 CN CN201480052171.7A patent/CN105579450B/zh active Active
- 2014-07-22 PL PL14758605T patent/PL3024833T3/pl unknown
- 2014-07-22 EA EA201600124A patent/EA030323B1/ru unknown
- 2014-07-22 NO NO14758605A patent/NO3024833T3/no unknown
- 2014-07-22 AP AP2016008990A patent/AP2016008990A0/xx unknown
- 2014-07-22 MA MA38803A patent/MA38803A1/fr unknown
-
2016
- 2016-01-08 PH PH12016500057A patent/PH12016500057A1/en unknown
- 2016-01-12 CL CL2016000063A patent/CL2016000063A1/es unknown
- 2016-01-13 DO DO2016000014A patent/DOP2016000014A/es unknown
- 2016-01-15 ZA ZA2016/00350A patent/ZA201600350B/en unknown
- 2016-01-15 CR CR20160031A patent/CR20160031A/es unknown
- 2016-01-21 SA SA516370448A patent/SA516370448B1/ar unknown
- 2016-01-21 NI NI201600015A patent/NI201600015A/es unknown
- 2016-01-21 IL IL243742A patent/IL243742B/en active IP Right Grant
- 2016-01-22 GT GT201600017A patent/GT201600017A/es unknown
- 2016-09-06 HK HK16110596.9A patent/HK1222394A1/zh unknown
- 2016-10-04 HK HK16111561.8A patent/HK1223360A1/zh not_active IP Right Cessation
-
2017
- 2017-11-14 HR HRP20171752TT patent/HRP20171752T1/hr unknown
- 2017-12-05 CY CY20171101271T patent/CY1119652T1/el unknown
-
2018
- 2018-02-27 US US15/906,389 patent/US10414754B2/en active Active
-
2019
- 2019-08-06 US US16/532,834 patent/US20190359595A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD4643C1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| PH12016501898A1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
| MX2016007311A (es) | Metodos para tratar canceres. | |
| TW201613593A (en) | Molecules for administration to ROS1 mutant cancer cells | |
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| GB201209613D0 (en) | New compounds | |
| MX361218B (es) | Análogos de spliceostatina. | |
| NZ738459A (en) | New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| MX2015017964A (es) | Inhibidores de bromodominio. | |
| MX360404B (es) | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. | |
| MX356205B (es) | Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr). | |
| NZ726365A (en) | Combinations for treating cancers | |
| MX350539B (es) | Compuestos de enediino, conjugados de los mismos y sus usos y metodos. | |
| MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
| MX2017004661A (es) | 17alfa-benzoato de cortexolona para uso en el tratamiento de tumores. | |
| MX359656B (es) | Derivados de oxoquinazolinil-butanamida. | |
| MX2016016388A (es) | Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña. | |
| MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
| MX2016008042A (es) | Derivados de imidazopirazinona. | |
| MX2020000135A (es) | Nuevos compuestos de quinolinona. | |
| MX2020012611A (es) | Composiciones liofilizadas de alta area de superficie que comprenden arsenico para administracion oral en pacientes. | |
| PH12016501997B1 (en) | Cycloalkyl-linked diheterocycle derivatives | |
| MX2015012386A (es) | Inhibidores de la cinasa cdk9. | |
| MX2018004696A (es) | Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG4A | Patent for invention issued | ||
| TH4A | Change/correction in patent specification |
Free format text: CHANGE OF APPLICANT ADDRESS |
|
| KA4A | Patent for invention lapsed due to non-payment of fees (with right of restoration) | ||
| MM4A | Patent for invention definitely lapsed due to non-payment of fees |